Biologics Inflection Point: Managing Risk From Biosimilar Competition
Posted: April 23, 2014
By: L.E.K. Consulting
In this Executive Insights, L.E.K. Consulting argues that the future success of blockbuster branded biologics hinges on the response of three key stakeholder groups who will play a role in biosimilar adoption—prescribers, patients and payers. Examining these stakeholders in detail, the authors explore a subset of strategies for engagement which underpin an enhanced ability to compete and win in this new and challenging market landscape.
Share this content with your network.
By clicking this 'Download Now' box, you consent to BioCentury forwarding your information
to the company that wrote this White Paper and you agree that said company can use